Selecta Biosciences, Inc. P/B ratio

P/B ratio of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.


Highlights and Quick Summary

Current P/B ratio of Selecta Biosciences, Inc. is 0.0 (as of December 30, 2020)
  • P/B ratio for the quarter ending March 30, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly P/B ratio decreased by -100.0%
  • Annual P/B ratio for 2020 was 0.0 (a -100.0% decrease from previous year)
  • Annual P/B ratio for 2019 was 14.83 (a Infinity% increase from previous year)
  • Annual P/B ratio for 2018 was 0.0 (a -100.0% decrease from previous year)
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of Selecta Biosciences, Inc.

Most recent P/B ratioof SELB including historical data for past 10 years.

Interactive Chart of P/B ratio of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0
2020 0.0 0.0 0.0
2019 14.83 1409.73 6.56 14.83
2018 0.0
2017 4.04 6.42 4.78 6.44 4.04
2016 3.3 3.94 0.68 0.0 3.3
2015 0.0 0.0 0.0
2014 0.0

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.